Drug intelligence / Profile preview

Flamitab

Development stage: Unknown
Lead developer: Wilson Drugs & Pharmaceuticals
Administration: Oral

Overview

Flamitab is an Ayurvedic herbal tablet developed by Wilson Drugs & Pharmaceuticals for the management of joint-related disorders. It is formulated with a synergistic blend of traditional natural ingredients, including Salai Guggulu (*Boswellia serrata*), Guggulu (*Commiphora mukul*), Rasna (*Pluchea lanceolata*), Ashwagandha (*Withania somnifera*), Dalchini (*Cinnamomum zeylanicum*), Trikatu, and Shilajit extract, along with decoctions of Guduchi, Rasna, and Gokhru. Flamitab is indicated for the treatment of arthritis, osteoarthritis, rheumatoid arthritis, spondylosis, rheumatism, and sciatica. The formulation works by reducing inflammation and swelling, strengthening muscles and bones, improving joint lubrication and flexibility, and supporting the repair and rebuilding of joint tissues.

Brand names: Flamitab
Other names: Flamitab Tablets

Beyond the preview

Go deeper on Flamitab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flamitab.